Atlas Trials

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Clinical trial NCT06229145 · COMPLETED

Trial details

NCT number
NCT06229145
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Gout
Start date
2024-03-18
Primary completion
2025-07-30
Enrollment
262

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.